BioSpace News Archive

SUSTAINEXT PROJECT: SHOWCASING A NEXT-GENERATION, ZERO-WASTE, DYNAMIC MODEL OF BIOREFINERY FROM EXTREMADURA TO THE BIO-BASED INDUSTRY IN THE EU

The first European-funded CBE flagship for botanical extract manufacturing

June 21, 2023
·
6 min read
Biotech Beach

Zymo Research donates $25,000 to support Center for Virus Research at the University of California, Irvine

Zymo Research, a leading innovation company for biomedical products and services has donated $25,000 to the Regents of the University of California to support the Center for Virus Research at the University of California, Irvine.

June 21, 2023
·
3 min read
FDA

US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older

The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.

June 21, 2023
·
13 min read
Genetown

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential

ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), announced its founding with a $23 million seed financing led by F-Prime Capital with Omega Funds.

June 21, 2023
·
8 min read
Business

Alentis Therapeutics Appoints Prof. David Jayne and Prof. Josep Tabernero to its Scientific Advisory Board

Alentis Therapeutics announced today the appointment of Professor David Jayne, Professor of Clinical Autoimmunity at Cambridge University and Professor Josep Tabernero, Head of Medical Oncology at Vall d’Hebron University Hospital as members of its Scientific Advisory Board.

June 21, 2023
·
4 min read
Drug Development

PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders

PureTech Health plc today announced the initiation of a Phase 2a proof-of-concept clinical trial of LYT-300 (oral allopregnanolone) in healthy volunteers using a validated clinical model of anxiety.

June 21, 2023
·
10 min read
Drug Development

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody

Arbutus Biopharma Corporation today announced that the first patient has been dosed in the additional treatment arm of the AB-729 Phase 2a triple combination clinical trial that has been expanded to include a PD-1 monoclonal antibody, nivolumab.

June 21, 2023
·
7 min read
Webinar on Addressing MARSI in Vascular Access: The Role of Skin Integrity in Infection Prevention, Presented by Covalon

Covalon Technologies Ltd. today announced an expert-led webinar titled “Addressing MARSI in Vascular Access: The Role of Skin Integrity in Infection Prevention” will be held on Thursday, June 22, 2023 at 1pm ET.

June 21, 2023
·
5 min read
Drug Development

New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented efficacy, safety and patient-reported outcome (PRO) data at ENDO 2023 for paltusotine, an experimental, once-daily, oral, small molecule somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for the treatment of acromegaly.

June 21, 2023
·
8 min read
Deals

Ocean Biomedical (NASDAQ: OCEA) Announces Share Price Target Increase to $17.63 by Fundamental Research Corp. on Positive Results from Independent Study Showing Glioblastoma Tumor Suppression, Received Patents, and Recent Financing

Ocean Biomedical, Inc. announced today that an equity analyst coverage report issued by Fundamental Research Corp. (“FRC”) has increased FRC’s price target of OCEA stock to $17.63 per share, up from FRC’s initial report in March 2023 of $16.40.

June 21, 2023
·
8 min read